Rangering i aksjer
#18692
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused... Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Aksjekurs
$4.58
Sist synkronisert: 2025-02-06
Handel Axcella Health Inc. (AXLA)
Pris AXLA pris med markedsverdi på B
Markedsverdi av Axcella Health Inc.(AXLA)
Markedsverdi: $189.73M
Per August 2026 har Axcella Health Inc. en markedsverdi på $189.73M. Dette gjør Axcella Health Inc. til det 18692nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Axcella Health Inc. fra 2019 til 2026
AXLA sammenlignet med topp 5 mest populære stocks
| Pris på AXLA |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.088T
|
+2,681,511.29%
|
|
|
|
|
$4.629T
|
+2,439,708.64%
|
|
|
|
|
$4.118T
|
+2,170,118.93%
|
|
|
|
|
$3.687T
|
+1,943,019.60%
|
|
|
|
|
$2.800T
|
+1,475,480.92%
|
